Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer-Reference-Cited by-同舟云学术

Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

Published:2010-08-28 Issue:6 Volume:67 Page:1363-1368
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kunisaki Chikara,Takahashi Masazumi,Makino Hirochika,Oshima Takashi,Fujii Shoichi,Takagawa Ryo,Kimura Jun,Kosaka Takashi,Ono Hidetaka A.,Akiyama Hirotoshi,Kameda Kunio,Kito Fumihiko,Morita Satoshi,Endo Itaru

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1433-7.pdf

Reference17 articles.

1. Jemar A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

2. Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557

3. Lee SJ, Cho SH, Yoon JY et al (2009) Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Cancer Chemother Pharmacol 65:159–166

4. Morita S, Nakata B, Tsuji A et al (2007) A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27–9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. Jpn J Clin Oncol 37:924–929

5. Koizumi W, Akiya T, Sato A, Tokyo cooperative oncology group (TCOG GI Group) et al (2009) Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Jpn J Clin Oncol 39:713–719

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial;Nature Communications;2024-01-02

2. Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study;Journal of the National Cancer Center;2023-06

3. Curative-Intent Surgery for Stage IV Advanced Gastric Cancer: Who Can Undergo Surgery and What Are the Prognostic Factors for Long-Term Survival?;Annals of Surgical Oncology;2019-09-16

4. Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis;Disease Markers;2016

5. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer;Cancer Chemotherapy and Pharmacology;2015-05-27